<DOC>
	<DOCNO>NCT01890993</DOCNO>
	<brief_summary>This study conduct Europe . The aim study demonstrate clinical effectiveness safety liraglutide dipeptidyl peptidase-4 ( DPP-4 ) inhibitor therapy routine primary care Europe .</brief_summary>
	<brief_title>Retrospective Collection Effectiveness Safety Data From Patients Treated With Liraglutide DPP-4 Inhibitor Primary Care Europe</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Patients treat liraglutide DPP4 inhibitor , accord license respective participate country data available 12 ( +/ 2 ) month Patients treat liraglutide DPP4 inhibitor , outside license respective participate country</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>